How to submit an article
Submission: submission@europeanreview.org
ISI Journal Citation Reports® Ranking: 2010, Pharmacology & Pharmacy
Impact Factor: 0.922
Instructions for Authors
European Review for Medical and Pharmacological Sciences (Eur Rev Med Pharmacol Sci) publishes Editorials, Reviews, Original Papers, and Scientific Correspondence on subjects regarding Experimental, Laboratory and Clinical Medicine, and Pharmacology. Eur Rev Med Pharmacol Sci is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses. Reviews should include systematic revision of the literature concerning the topics treted and preferably meta-analyses, original illustration and tables. European Review for Medical and Pharmacological Sciences doesn't accept for the pubblication "data not shown" or "unpublished data". Letters are restricted to the discussion of papers already published in the journal, with a maximum of 300 words, one table or figure and up to ten references.
Short Reports and Case Reports will be considered for publication only if of particular interest. 
The maximum length is 1500 words, excluding abstract, references, tables and figures. The structured abstract must not exceed 200 words.
Manuscript Submissions
Authors should submit manuscripts including figures to the Eur Rev Med Pharmacol Sci website submission@europeanreview.org – Website: http://www.europeanreview.org – Please read and apply the loading instructions given at this site, noting that all informations entered during the submission process related to the manuscript should also be included, and be identical to the final submitted version of the manuscript – please see full details under "Presentation of Manuscripts". Papers must be submitted exclusively to the Journal, and are accepted on the understanding that they have not been, and will not be, published elsewhere. The submission process requires a full declaration of personal interests of all Authors, and funding interests; these details should also be included in the text of the manuscript (see below).
Please note that the journal employs a plagiarism detection system. By submitting your manuscript to the journal you accept that your manuscript may be screened for plagiarism against previously published work.
Authorship
Authors must fulfil the following criteria:
- He/she must have made a substantial contribution to research design, or the acquisition, analysis or interpretation of data;
- He/she must have drafted the paper or revising it critically;
- He/she must have given approval of the submitted and final versions.
Copyright Transfer Agreement: All Eur Rev Med Pharmacol Sci Authors will be required to sign a Copyright Transfer Agreement (click to download PDF) for all papers accepted for publication. Signature of the CTA is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. After submission, Authors will retain the right to publish their paper in various media/circumstances. To assist Authors, an appropriate CTA form will be supplied by the editorial office. The original completed Copyright Transfer Agreement must be signed by the corresponding Author and sent by e-mail to European Review for Medical and Pharmacological Sciences. If a paper is accepted for publication, and this form has not been received, there will be a delay in the edited paper appearing in the forthcoming section on the Eur Rev Med Pharmacol Sci website. The Editors retain the usual right to modify the style and length of a contribution (major changes being agreed with the corresponding Author) and to decide the time of publication.
SuperFast Papers
We offer a separate fast appraisal and publication service for manuscripts. A submission fee of Euro 1,000 (plus VAT in Italy), guarantees full peer review within 10 working days, but it does not guarantee acceptance. Once a manuscript is accepted in its final form, it will be published as a forthcoming paper (the abstract only) within 20 to 30 days, and in a full issue of the journal about one month later; full details below.
Note: there is an additional fee – Euro 300.00 – for the articles (black and white printing, and including 4 figures and 4 half page tables) up to sixteen pages in length (54,000 characters spaces included).
This service will not slow the standard prompt service provided by the journal.
Authors planning to submit a SuperFast paper are encouraged to contact Gianni Lombardi in the Editorial Office in advance of submission, so that peer review can be planned in advance (g.lombardi@verduci.it). An invoice will be issued by Verduci Editore for the submission fee on receipt of an initial request to use our "Superfast" process – please provide full details to whom this invoice should be sent (including an email address and/or fax number). This procedure will not be active from July 10 to August 31.
Presentation of Manuscripts
The manuscript should be typed (with a wide margin) and double-spaced. Authors should retain one copy of all material, as the Editors cannot accept responsibility for loss of, or damage to, a manuscript.
A title page should contain the Authors' names, appointments and place of work at the relevant time, plus the full contact details of the Corresponding Author including their current e-mail address. A full and a short running title should be given, together with a small number of key words for indexing purposes.
The text should start with a structured Abstract, not exceeding 270 words, organized into sections using all of the following headings Background, Aim, Materials and Methods, Results, Conclusions. The paper should then proceed conventionally: Introduction, Materials and Methods, Results, Discussion, and References (list all Authors and put the numbers in sequence in the text). Pages should be numbered consecutively in Arabic numerals, but tables, footnotes, figure legends (including magnifications), acknowledgements and declaration of interests must be submitted on separate sheets. Review Articles and Systematic Reviews also require a structured summary using all of the following headings: Background, Aim, Materials and Methods (e.g. search terms used), Results (avoid vague statements e.g. '...will be discussed'), Conclusions (e.g. need for future studies). Reporting Clinical Trials Conducted by Pharmaceutical Companies Please ensure that clinical trials sponsored by pharmaceutical companies follow the guidelines on Good Publication Practice: http://www.gpp-guidelines.org. These guidelines aim to ensure that such trials are published in a responsible and ethical manner. The guidelines cover companies' responsibility to endeavour to publish results of all studies, companies' relations with investigators, measures to prevent redundant or premature publication, methods to improve trial identification, and the role of professional medical writers.
Illustrations
Figure legends should be included in the main text of the manuscript and not form part of the figures. For production purposes, it is best if you can supply figures in TIFF format; however, it is also possible to use Illustrator or Photoshop software saved in the format ‘.eps’, ‘.tif’ or ‘.jpg’. If you are unable to provide these specified formats, please provide the figures in as many different file formats as soon as possible.
The figure resolution/specification for various types of original figures, at their final size, should be as follows: Line art – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Halftone (i.e. both B/W and Colour photographs) – Minimum 300 dpi , measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Line and tone (line art and halftone combined) – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size.
For line figures, the lines should be solid, the text in a standard font and not blurred, and the overall image should be sharp and clear. Avoid using tints if possible; if they are essential to the understanding of the figure, try to make them coarse. As a guide, if the electronic files are viewed at 400% on the computer screen and they look blurred or pixellated in any way then they will NOT be of sufficient quality for printing.
Figure and table legends must be able to stand alone in the text and thus full descriptive legends for all figures and tables should be supplied.
Units and Abbreviations
All measurements should be in SI units with the exception of haemoglobin (g/dL) and blood pressure (mmHg). Original observations recorded in other units should be stated, together with the appropriate conversion factors. Standard abbreviations, without punctuation, are used. Units, Symbols and Abbreviations (1988) published by the Royal Society of Medicine, and SI: The International System of Units (1982) from HMSO both provide useful guides. Abbreviations, used sparingly, should follow the first full spelling, in parentheses. A list of abbreviations at the beginning of the article is accepted only if they are more than 8.
Statistics
Methods should be referenced. Two-tailed significance tests should be used unless explicitly stated. Controls should be described as completely as experimental subjects. Measures of location should be accompanied by measures of variability (e.g. mean and confidence intervals) as well as conventional probability values. Clinical trial reports should include the power of the study design.
Ethics
An Ethics Committee should have approved human and animal studies but in questionable matters the Editors reserve the right to reject papers.
Financial Support
Sources of financial support during the last two years must be acknowledged. Please read the following statements, adding those sections which are relevant at the end of your submitted manuscript under a heading 'Statement of Interests'.
- Authors' declaration of personal interests: (i) [Name of individual] has served as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. (ii) [Name of individual] is an employee of [name of organization]. (iii) [Name of individual] owns stocks and shares in [name of organization]. (iv) [Name of individual] owns patent [patent identification and brief description].
- Declaration of funding interests: (i) This study was funded [in part or in full] by [insert name of funding organization], grant number [insert grant or other identification number]. (ii) The [writing or preparation] of this paper was funded in part by [insert name of funding organization]. (iii) Initial data analyses were undertaken by [name of individuals if not listed as Authors] who are employees of [name company] and received funding from [insert name of funding organization]. (iv) Writing support was provided by [insert name of individual(s)] of [name company] and funded by [insert name of funding organization].
References
Use the Vancouver system. References should be numbered in the order in which they are first mentioned in the text, and should be identified in the text, tables and legends by Arabic numbers in superscript. List all the Authors. The form of references adopted by the US National Library of Medicine and used in Index Medicus applies. References must be verified by the Authors against the original documents.
Example: Jiang S-P, Wu Y-M, Guo S-F, Lv Z-Q. Decreased renal mRNA expression of TRPM6 is associated with hypomagnesemia in C57BL/6 asthmatic mice. Eur Rev Med Pharmacol Sci 2010; 14: 935-940.
Drug Names
Generic names should, in general, be used. If an Author so desires, brand names may be inserted in parentheses. Drug names are spelled out according to the European Pharmacopoeia, but the American spelling should be used after the first use of a drug name.
Proofs
The corresponding Author will receive an e-mail with a pdf file of the proof. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Excessive changes made by the Author in the proofs, excluding typesetting errors, will be charged separately.
Forthcoming Articles
Abstracts of the articles will appear 50-60 days after acceptance in the European Review for Medical and Pharmacological Sciences Forthcoming section. Abstracts of the articles are, therefore, available as soon as they are ready, rather than having to wait for the next scheduled print issue. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are, therefore, given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. Forthcoming article is also a way to know if a paper has been accepted.
Reprints
Paper reprints shall be charged. Electronic offprints are sent to the first Author at his/her first email address on the title page of the paper, on request. For this reason, please ensure that the name, address and email address of the corresponding Author are clearly indicated on the manuscript title page if he/she is not the first Author of the paper.
Supplements
You can contact Gianni Lombardi (g.lombardi@verduci.it). Our team will be able to provide advice and quotations for supplements.
Cost of Publication
Starting on all articles submitted from September 2011, the following prices apply:
The articles (black and white printing, and including 1 figure and 1 half page table) up to four pages in length (13,500 characters spaces included) are published without charge.
The articles (black and white printing, and including 2 figures and 2 half page tables) up to eight pages in length (27,000 characters spaces included) are published at a regular standard price:
as of 10 September 2011 the regular standard price is Euro 350.00.
The articles (black and white printing, and including 4 figures and 4 half page tables) up to sixteen pages in length (54,000 characters spaces included) are published at a regular standard price:
as of 10 September 2011 the regular standard price is Euro 800.00.
The articles over sixteen pages in length shall be charged as established via previous agreements.
Additional tables will cost Euro 40.00 each. Additional figures will cost Euro 40.00 each.
The cost of color pages is Euro 300.00 each.
Works made by Researchers from developing countries may be subject to special conditions/benefits.